Meeting
2016 ASCO Annual Meeting
T-DM1 to induce response in central nervous system (CNS) metastases from Her2 +ve metastatic breast cancer (MBC).
Authors
Yamini McCABE
The Christie NHS Foundation TRUST, Manchester, United Kingdom
Yamini McCABE , Andrew M. Wardley , Anne Caroline Armstrong , Sacha Jon Howell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 34, 2016 (suppl; abstr 582)
DOI
10.1200/JCO.2016.34.15_suppl.582
Abstract #
582
Poster Bd #
70
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets).
First Author: Cristiano Ferrario
Poster
2021 ASCO Annual Meeting
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
First Author: Giuseppe Curigliano
Poster
2021 ASCO Annual Meeting
HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).
First Author: Ian E. Krop
Poster
2017 ASCO Annual Meeting
Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P).
First Author: Ander Urruticoechea